Focus: Danaher is a $23.9B diversified conglomerate headquartered in Washington, DC with 50,000+ employees, operating primarily in diagnostics and life sciences instrumentation with a significant public market presence (DHR ticker).
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Hot — 1781 jobs added in 30d
Net +1019 (1781 new, 762 removed). Aggressive expansion phase.
Danaher suits professionals seeking stable, large-scale operations and diagnostic/instrumentation expertise, but not those prioritizing drug R&D velocity or a traditional pharma science track.
Help build intelligence for Danaher
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Danaher's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
This Week's Top 5: Roche, TCS, GSK, Danaher, Daiichi Sankyo - Healthcare Digital
This Week's Top 5: Roche, TCS, GSK, Danaher, Daiichi Sankyo Healthcare Digital
Danaher names Julie Sawyer Montgomery as president and CEO - The Pharma Letter
Danaher names Julie Sawyer Montgomery as president and CEO The Pharma Letter
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead? - qz.com
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead? qz.com
Murali Venkatesan, Ph.D., global head of Danaher Ventures, to present at the 13th Aging Research & Drug Discovery (ARDD) Meeting in Boston - EurekAlert!
Murali Venkatesan, Ph.D., global head of Danaher Ventures, to present at the 13th Aging Research & Drug Discovery (ARDD) Meeting in Boston EurekAlert!
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC) The Globe and Mail
Danaher’s revenue outlook cut, biotech miss overshadow profit forecast lift - 1470 & 100.3 WMBD
Danaher’s revenue outlook cut, biotech miss overshadow profit forecast lift 1470 & 100.3 WMBD
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Community-based "X-ray+Xpert® MTB/RIF ultra pooling test" case-finding strategy among high-risk groups in rural areas: a prospective application study.
Analytical and Clinical Validity of a High-Throughput, Fully Automated Immunoassay for Plasma Neurofilament Light Chain.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo